Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” study
Narendranath Epperla(University of Utah), Timothy S. Fenske(Medical College of Wisconsin), Jonathon B. Cohen(Emory University), Mehdi Hamadani(Medical College of Wisconsin), Vaishalee P. Kenkre(University of Wisconsin–Madison), Amanda F. Cashen(Washington University in St. Louis), Parameswaran Hari(Medical College of Wisconsin), Eunhye Oak(Washington University in St. Louis), Michael Tallarico(University of Chicago), Abraham S. Kanate(HonorHealth), Nilanjan Ghosh(Levine Cancer Institute), Luke Farmer(Carolinas Healthcare System), Oscar Calzada(Emory University), Kwang Woo Ahn(Medical College of Wisconsin), Chadi Nabhan(University of Chicago), Luciano J. Costa(University of Alabama at Birmingham)
Cited by 68
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735